BakerKS, SyrjalaKL. Long-term complications in adolescent and young adult leukemia survivors. Hematology Am Soc Hematol Educ Program. 2018; 2018(1):146–53.
O'DwyerK, FreyerDR, HoranJT. Treatment strategies for adolescent and young adult patients with acute myeloid leukemia. Blood. 2018; 132(4):362–8.
4.
WolfsonJ, SunCL, WyattL, et al.Adolescents and young adults with acute lymphoblastic leukemia and acute myeloid leukemia: impact of care at Specialized Cancer Centers on Survival Outcome. Cancer Epidemiol Biomarkers Prev. 2017; 26(3):312–20.
5.
WoodsWG, FranklinARK, AlonzoTA, et al.Outcome of adolescents and young adults with acute myeloid leukemia treated on COG trials compared to CALGB and SWOG trials. Cancer. 2013; 119(23):4170–9.
6.
NasriSS, GiriS, NunneryS, et al.Outcome of adolescents and young adults compared with pediatric patients with acute myeloid and promyelocytic leukemia. Clin Lymphoma Myeloma Leuk. 2017; 17(2):126–32.e1.
7.
GuptaS, BaxterNN, SutradharR, et al.Adolescents and young adult acute myeloid leukemia outcomes at pediatric versus adult centers: a population-based study. Pediatr Blood Cancer. 2021; 68(8):e28939.
PDQ Pediatric Treatment Editorial Board. Childhood acute myeloid leukemia/other myeloid malignancies treatment (PDQ®): Health Professional Version, in PDQ Cancer Information Summaries. Bethesda, MD: National Cancer Institute (US); 2002.
10.
Pollyea DA (Ed). NCCN, National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology for acute myeloid leukemia. National Comprehensive Cancer Network; Version 1.2022.
11.
Shah B (Ed). NCCN, National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology for acute lymphoblastic leukemia. National Comprehensive Cancer Network; Version 1.2022.
12.
RadtkeI, MullighanCG, IshiiM, et al.Genomic analysis reveals few genetic alterations in pediatric acute myeloid leukemia. Proc Natl Acad Sci U S A. 2009; 106(31):12944–9.
13.
TarlockK, ZhongS, HeY, et al.Distinct age-associated molecular profiles in acute myeloid leukemia defined by comprehensive clinical genomic profiling. Oncotarget. 2018; 9(41):26417–30.
14.
GibsonBES, WebbDKH, HowmanAJ, et al.Results of a randomized trial in children with acute myeloid leukaemia: medical research council AML12 trial. Br J Haematol. 2011; 155(3):366–76.
15.
WheatleyK, BurnettAK, GoldstoneAH, et al.A simple, robust, validated and highly predictive index for the determination of risk-directed therapy in acute myeloid leukaemia derived from the MRC AML 10 trial. United Kingdom Medical Research Council's Adult and Childhood Leukaemia Working Parties. Br J Haematol. 1999; 107(1):69–79.
16.
MrózekK, MarcucciG, NicoletD, et al.Prognostic significance of the European LeukemiaNet standardized system for reporting cytogenetic and molecular alterations in adults with acute myeloid leukemia. J Clin Oncol. 2012; 30(36):4515–23.
17.
SekeresMA, GuyattG, AbelG, et al.American Society of Hematology 2020 guidelines for treating newly diagnosed acute myeloid leukemia in older adults. Blood Adv. 2020; 4(15):3528–3549.
18.
LeeJH, JooYD, KimH, et al.A randomized trial comparing standard versus high-dose daunorubicin induction in patients with acute myeloid leukemia. Blood. 2011; 118(14):3832–41.
19.
FernandezHF, SunZ, YaoX, et al.Anthracycline dose intensification in acute myeloid leukemia. N Engl J Med. 2009; 361(13):1249–59.
20.
JohnstonDL, AlonzoTA, GerbingRB, et al.Central nervous system disease in pediatric acute myeloid leukemia: a report from the Children's Oncology Group. Pediatr Blood Cancer. 2017; 64(12). DOI:10.1002/pbc.26612
21.
AlakelN, StölzelF, MohrB, et al.Symptomatic central nervous system involvement in adult patients with acute myeloid leukemia. Cancer Manag Res. 2017; 9:97–102.
22.
CreutzigU, van den Heuvel-EibrinkMM, GibsonB, et al.Diagnosis and management of acute myeloid leukemia in children and adolescents: recommendations from an International Expert Panel. Blood. 2012; 120(16):3187–205.
23.
PercivalME, LaiC, EsteyE, et al.Bone marrow evaluation for diagnosis and monitoring of acute myeloid leukemia. Blood Rev. 2017; 31(4):185–92.
24.
TerwijnM, van PuttenWLJ, KelderA, et al.High prognostic impact of flow cytometric minimal residual disease detection in acute myeloid leukemia: data from the HOVON/SAKK AML 42A study. J Clin Oncol. 2013; 31(31): 3889–97.
25.
LokenMR, AlonzoTA, PardoL, et al.Residual disease detected by multidimensional flow cytometry signifies high relapse risk in patients with de novo acute myeloid leukemia: a report from Children's Oncology Group. Blood. 2012; 120(8):1581–8.
26.
RubnitzJE, KaspersGJL. How I treat pediatric acute myeloid leukemia. Blood. 2021; 138(12):1009–18.
27.
TsukimotoI, TawaA, HoribeK, et al.Risk-stratified therapy and the intensive use of cytarabine improves the outcome in childhood acute myeloid leukemia: the AML99 trial from the Japanese Childhood AML Cooperative Study Group. J Clin Oncol. 2009; 27(24):4007–13.
28.
XuanL, WangY, HuangF, et al.Sorafenib maintenance in patients with FLT3-ITD acute myeloid leukaemia undergoing allogeneic haematopoietic stem-cell transplantation: an open-label, multicentre, randomised phase 3 trial. Lancet Oncol. 2020; 21(9):1201–12.
29.
DingfieldL, CasarettD, BenderL, et al.How are pediatric hospice patients different than adults? Results of a Multicenter Cohort Study (S717). J Pain Symptom Manage. 2014; 47(2):475.
CreutzigU, RitterJ, RiehmH, et al.Improved treatment results in childhood acute myelogenous leukemia: a report of the German cooperative study AML-BFM-78. Blood. 1985; 65(2):298–304.
33.
BurnettAK, RussellNH, HillsRK, et al.Optimization of chemotherapy for younger patients with acute myeloid leukemia: results of the medical research council AML15 trial. J Clin Oncol. 2013; 31(27):3360–8.
34.
GhafoorT, AhmedS, KhalilS, et al.Optimum induction chemotherapy for pediatric acute myeloid leukemia: experience from a developing country. J Pediatr Pharmacol Ther. 2020; 25(4):288–94.
